Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
assessing, began, breach, compounded, customary, GLP, investor, recoverability, repaid, resume, unsettled, waive
Removed:
account, begin, calculated, liable, repurchase, wholly
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Eric Pauwels Employment Agreement
- 10.2 Exclusive Patent License Agreement Between the Registrant and Glaxosmithkline LLC Dated July 29, 2011
- 10.3 First Amendment to the Development and License Agreement Between the Registrant and Amgen Inc.
- 10.4 Second Amendment to the Development and License Agreement Between the Registrant and Amgen Inc.
- 10.5 Third Amendment to the Development and License Agreement Between the Registrant and Amgen Inc.
- 10.7 Manufacturing Agreement Between Registrant and Synco Bio Partners B.V. Dated August 1, 2009
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
- PDF 10-Q
- 10.1 Eric Pauwels Employment Agreement
- 10.2 Exclusive Patent License Agreement Between the Registrant and Glaxosmithkline LLC Dated July 29, 2011
- 10.3 First Amendment to the Development and License Agreement Between the Registrant and Amgen Inc.
- 10.4 Second Amendment to the Development and License Agreement Between the Registrant and Amgen Inc.
- 10.5 Third Amendment to the Development and License Agreement Between the Registrant and Amgen Inc.
- 10.7 Manufacturing Agreement Between Registrant and Synco Bio Partners B.V. Dated August 1, 2009
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
Related press release
NPSP similar filings
External links